GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Total Current Liabilities

Gilead Sciences (BUE:GILD) Total Current Liabilities : ARS4,072,080 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gilead Sciences's total current liabilities for the quarter that ended in Dec. 2023 was ARS4,072,080

Gilead Sciences Total Current Liabilities Historical Data

The historical data trend for Gilead Sciences's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Total Current Liabilities Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 583,330.56 927,487.83 1,172,493.88 1,884,050.65 4,072,080.00

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,884,050.65 2,079,608.90 3,351,359.97 4,180,152.87 4,072,080.00

Gilead Sciences Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gilead Sciences's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2007160.002+649078.001
+Other Current Liabilities+Current Deferred Liabilities
=1415842.001+0
=4,072,080

Gilead Sciences's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2007160.002+649078.001
+Other Current Liabilities+Current Deferred Liabilities
=1415842.001+0
=4,072,080

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gilead Sciences Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Total Current Liabilities
Comparable Companies
BMY BIIB AMGN PFE OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:ROG XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.